ADMA
NASDAQ · Biotechnology
Adma Biologics Inc
$8.17
-0.30 (-3.54%)
Performance
1D
—
1W
—
1M
—
3M
-50.09%
6M
-49.03%
1Y
-60.05%
YTD
-54.31%
Open$8.65
Previous Close$8.47
Day High$8.92
Day Low$8.02
52W High$23.98
52W Low$7.21
Volume—
Avg Volume8.63M
Market Cap2.00B
P/E Ratio13.64
EPS$0.60
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$17.86
Below
SMA 200
$17.61
Below
RSI (14)
42.2
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
9 analysts
Price Target
+331.1% upside
Current
$8.17
$8.17
Target
$35.22
$35.22
$21.76
$35.22 avg
$46.82
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 511.17M | 342.98M | 922.90M |
| Net Income | 147.21M | 88.89M | -95,808,796 |
| Profit Margin | 28.8% | 27.4% | -10.4% |
| EBITDA | 188.41M | 120.10M | -107,012,515 |
| Free Cash Flow | — | — | -83,155,340 |
| Rev Growth | +49.0% | +49.0% | +20.1% |
| Debt/Equity | 0.15 | 0.15 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |